|
Real-world 177Lu-DOTATATE peptide receptor radionuclide therapy: Treatment outcomes with dosing variations and in non-midgut neuroendocrine tumors. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - GE Healthcare |
Travel, Accommodations, Expenses - GE Healthcare |
| |
|
Employment - Bristol-Myers Squibb (I); Janssen Oncology (I) |
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene (I) |
Consulting or Advisory Role - Merck |
Research Funding - Arcus Biosciences (Inst); AstraZeneca/MedImmune (Inst); Genentech (Inst); Gilead Sciences (Inst); Hutchison MediPharma (Inst); MedImmune (Inst); Merck (Inst); Oncolys BioPharma (Inst); Seagen (Inst); Tarveda Therapeutics (Inst); Xencor (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb (I); Janssen Oncology (I) |
| |
|
Other Relationship - Epigenomics; Freenome; Guardant Health; Immunovia; Janssen; Recusion; Recusion; Universal Diagnostics |
(OPTIONAL) Uncompensated Relationships - Ambry Genetics; GenDx; InVitae; Myriad Genetics |
| |
|
No Relationships to Disclose |